fbpx

This MS drug switch means fewer relapses in study

This MS drug switch means fewer relapses in studyPublished: 30 November 2022 People with multiple sclerosis (MS) who switched from Gilenya (fingolimod) experienced fewer relapses than those who changed to Tysabri (natalizumab) or Mavenclad (cladribine) in a new study. The research included data from 1,045 patients from 26 countries. Each
Read More

Stopping this DMT during pregnancy increases relapse-related disability risk

Stopping this DMT during pregnancy increases relapse-related disability risk Published: 08 February 2022 People with multiple sclerosis (MS) who stop taking Tysabri (natalizumab) during pregnancy have a significant risk of relapse-related disability, a new study has found.  Researchers analysed data of 255 pregnant women from the German Multiple Sclerosis and
Read More

New clues for predicting rare brain infection linked to MS drug

New clues for predicting rare brain infection linked to MS drugPublished: 05 October 2021 A new study has found that John Cunningham virus mutations may be an early predictor for brain infection in people receiving Tysabri for multiple sclerosis (MS).  Tysabri works by preventing immune cells from entering the brain
Read More

Switching from Tysabri to moderate-efficacy DMTs linked to worse outcomes in MS

Switching from Tysabri to moderate-efficacy DMTs linked to worse outcomes in MS Published: 26 February 2021 Switching from Tysabri (natalizumab) to moderate-efficacy disease-modifying therapies (DMTs) puts patients with multiple sclerosis (MS) at a higher risk of further disease activity and disability progression compared with those who switch to a high-efficacy
Read More

Switching from Tysabri increases risk of relapse

Switching from Tysabri increases risk of relapse Published: 18 June 2020 A new study has found the risk of a relapse for someone with relapsing remitting multiple sclerosis (RRMS) switching from Tysabri (natalizumab) to another injectable or oral after two or more years on the therapy is two to three
Read More